

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently admended): An enveloped pharmaceutical composition comprising:

three or more layers of phenylephrine deposited on a sustained release bead for extended release of over 80% of the phenylephrine between 90 minutes and 6 hours;

an immediate release layer of guaifenesin disposed on the three or more layers of phenylephrine wherein over 80% of the guaifenesin is released within 60 minute;

a coating in contact with the immediate release layer of guaifenesin; and

one or more inactives in contact with the coating, wherein the one or more excipients, are selected from excipients, plasticizers, coating excipients, anti-adherents, silica, polyethylene glycols, surfactants, waxes, stearic acid, stearic acid salts, stearic acid derivatives, starch, hydrogenated vegetable oils, sodium benzoate, sodium acetate, leucine, PEG, magnesium lauryl sulfate.

~~a first active in contact with a carrier available for immediate release, wherein over 80% of the first active is released within 60 minutes and the first active is guaifenesin; and~~

~~a second active disposed on a bead for extended release, wherein the second active comprises three or more layers of the phenylephrine; and~~

~~an extended release coating and wherein over 80% of the second active is released between 90 minutes and 6 hours.~~

Claims 2-5. Cancelled

Claim 6. (original) The composition of claim 1, wherein immediate release is defined further as comprising release of over 90% of the first active within about 90 minutes.

Claim 7. cancelled.

Claim 8. (original) The composition of claim 1, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.

Claim 9. cancelled

Claim 10. (currently admended) The composition of claim 1, wherein the guaifenesin ~~first active~~ comprises guaifenesin DC in a powder form.

Claim 11. (currently admended) The composition of claim 1, wherein the guaifenesin ~~first active~~ comprises 211 mg of 95% guaifenesin.

Claim 12-18. cancelled

Claim 19. (currently admended) The composition of claim 1, wherein the ~~first active for immediate release~~ guaifenesin comprises a powder form and the ~~second active~~ three or more layers of phenylephrine comprises a beaded form.

Claim 20. (previously presented) An enveloped pharmaceutical composition comprising:
a first active available for immediate release, wherein over 80% of the first active is released within about 60 minutes, wherein the first active is disposed on a first carrier; and
a second active available for extended release, wherein the first active effects a physiological result that improves the physiological action of the second active upon extended release, wherein the second active is disposed on an extended release bead and coated with an extended release coating.

Claim 21. (original) The composition of claim 20, wherein the first and second actives are enveloped in a single dose.

Claim 22-24. cancelled.

Claim 25. (original) The composition of claim 20, wherein immediate release is defined further as comprising release of over 90% of the first active within about 90 minutes.

Claim 26. (original) The composition of claim 20, wherein extended release is defined further as comprising release of over 80% of the second active within about 60 minutes to about 8 hours.

Claim 27. (original) The composition of claim 20, wherein extended release is defined further as comprising release of over 90% of the second active within about 90 minutes to about 6 hours.

Claim 28. (original) The composition of claim 20, wherein the second active for extended release is selected from the group consisting of a decongestant, an antihistamine, an expectorant,

an antitussive and mixtures thereof.

Claim 29. (previously presented) The composition of claim 20, wherein the first active comprises guaifenesin.

Claim 30. (previously presented) The composition of claim 20, wherein the first active comprises Guaifenesin DC in a powder form.

Claim 31. (previously presented) The composition of claim 20, wherein the first active comprises 211 mg of 95% guaifenesin.

Claim 32. (original) The composition of claim 20, wherein the second active comprises a nasal decongestant.

Claim 33. (original) The composition of claim 20, wherein the second active comprises phenylephrine.

Claim 34. (original) The composition of claim 20, wherein the second active comprises phenylephrine as a sustained release bead.

Claim 35. (original) The composition of claim 20, wherein the second active comprises phenylephrine as a layered sustained release bead.

Claim 36. (original) The composition of claim 20, wherein the second active comprises three or more layers of phenylephrine on a bead.

Claim 37. (original) The composition of claim 20, wherein the first active is superposed on the second active.

Claim 38. (original) The composition of claim 20, comprising further one or more inactives.

Claim 39. (original) The composition of claim 20, wherein the first active for immediate release comprises a powder form and the second active comprises a beaded form.

Claim 40. (currently amended) An enveloped pharmaceutical composition comprising:
three or more layers of phenylephrine deposited on sustained release beads for extended release of over 80% of the phenylephrine between 1 hour and 6 hours;
an immediate release layer of guaifenesin in contact with the three or more layers of phenylephrine wherein over 80% of the guaifenesin is released within 60 minute;

an enveloped single dose coating at least partially surrounding the immediate release layer of guaifenesin and the sustained release beads; and

one or more inactives in contact with the coating, wherein the one or more excipients, are selected from excipients, plasticizers, coating excipients, anti-adherents, silica, polyethylene glycols, surfactants, waxes, stearic acid, stearic acid salts, stearic acid derivatives, starch, hydrogenated vegetable oils, sodium benzoate, sodium acetate, leucine, PEG, magnesium lauryl sulfate.

~~a first active packaged so that over 90 % of the first active is released within about 90 minutes; and~~

~~a second active comprises three or more layers of phenylephrine on a bead for extended release, wherein over 90% of the second active is released between about 1 and 6 hours.~~

Claim 41. (currently admended) The composition of claim 40, wherein the guaifenesin first and the ~~second active~~ three or more layers of phenylephrine are disposed on separate carriers.

Claim 42-45. cancelled

Claim 46. (currently admended) The composition of claim 40, wherein immediate release is defined further as comprising release of over 90% ~~of the first active~~ within about 60 minutes.

Claim 47. (currently admended) The composition of claim 40, wherein extended release is defined further as comprising release of over 80% ~~of the second active~~ within about 60 minutes to about 8 hours.

Claim 48. (currently admended) The composition of claim 40, wherein extended release is defined further as comprising release of over 90% ~~of the second active~~ within about 90 minutes to about 6 hours.

Claim 49. cancelled

Claim 50. (currently admended) The composition of claim 40, wherein the ~~first active~~ guaifenesin comprises guaifenesin in a powder form.

Claim 51. (currently admended) The composition of claim 40, wherein the guaifenesin first active comprises 211 mg of 95% guaifenesin.

Claim 52-58 cancelled

Claim 59. (currently admended) The composition of claim 40, wherein the guaifenesin ~~first~~ ~~active for immediate release~~ comprises a powder form and the three or more layers of phenylephrine ~~second active~~ comprises a beaded form.

Claim 60. (previously presented) An enveloped pharmaceutical composition comprising:
a first active available for immediate effervescent release, wherein over 80% of the first active is released within about 60 minutes, wherein the first active is on a first carrier; and
a second active in a mini-tab for extended release selected from the group consisting of a decongestant, an antihistamine, an antitussive and mixtures thereof, wherein over 80% of the second active is release within about 90 minutes to about 6 hours and the second active disposed on a bead and coated with three or more layers of an extended release coating.

Claim 61. (previously presented) An enveloped pharmaceutical composition comprising:
a first active available for immediate release, wherein over 80% of the first active is released within about 60 minutes, wherein the first active is on a first carrier; and
a second active for extended release on a carrier wherein the second active is selected from the group consisting of a decongestant, an antihistamine, an antitussive and mixtures thereof wherein the first and second actives are different, wherein over 80% of the second active is release within about 90 minutes to about 6 hours and the second active is disposed on a bead and coated with three or more layers of an extended release coating.

Claims 62 – 80 cancelled.